The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

With over 10 million people affected worldwide, Parkinson's disease is the fastest-growing neurological disorder. More than ...

Region Genetic Association Analysis of Breast Cancer Patients With and Without Persistent Postsurgical Neuropathic Pain,” ...

Topline results were announced from a phase 3 trial evaluating cebranopadol for the treatment of moderate to severe acute pain in patients following ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

3-point decrease in the Skin Pain Numeric Rating Scale (NRS) score and Skin Pain NRS30. Furthermore, povorcitinib demonstrated rapid onset of response, including rapid skin pain reduction.

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

Tris' drug outperformed placebo on the main efficacy measure in the study – the pain numerical rate scale (NRS) area under the curve from four through 48 hours (AUC4-48) – which gives a ...